BPA
INMB icon

Beacon Pointe Advisors’s INmune Bio INMB Stock Holding History

Beacon Pointe Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7K Hold
10,368
– – ﹤0.01% 1825
2025
Q4 		$16.2K Hold
10,368
– – ﹤0.01% 1497
2025
Q3 		$21.5K Hold
10,368
– – ﹤0.01% 1374
2025
Q2 		$23.9K Hold
10,368
– – ﹤0.01% 1243
2025
Q1 		$81K Hold
10,368
– – ﹤0.01% 1190
2024
Q4 		$48.4K Buy
+10,368
New +$54.1K ﹤0.01% 1187
2024
Q2 		– Sell
-10,368
Closed -$122K – 1331
2024
Q1 		$122K Hold
10,368
– – ﹤0.01% 1298
2023
Q4 		$117K Hold
10,368
– – ﹤0.01% 1271
2023
Q3 		$70.2K Buy
+10,368
New +$86K ﹤0.01% 1299

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Beacon Pointe Advisors's INMB Position: Q1 2026 in Review

Beacon Pointe Advisors held its INmune Bio (INMB) position steady in Q1 2026 at 10,368 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Beacon Pointe Advisors first reported a position in INMB in Q3 2023 and has held it in 9 quarters since. The position peaked at $122K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Beacon Pointe Advisors held 10,368 shares of INmune Bio worth $11.7K as of Q1 2026.
  • Beacon Pointe Advisors left its INmune Bio share count unchanged in Q1 2026.
  • INmune Bio made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1825 holding.
  • Beacon Pointe Advisors first reported a position in INmune Bio in Q3 2023 and has held it in 9 quarters since.
  • Beacon Pointe Advisors's INmune Bio position peaked at $122K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.